Oligodendroglioma Market Research Report – Pipeline Review, H2 2017

“The Latest Research Report Oligodendroglioma-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Oligodendroglioma Market

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma-Pipeline Review, H2 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/1339581

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 6 and 11 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339581/oligodendroglioma-pipeline-review-h2-2017-market-research-reports.pdf

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Have Any Query? Ask Our Expert @ https://www.marketresearchreports.biz/sample/enquiry/1339581

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Oligodendroglioma-Overview 6

Oligodendroglioma-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Oligodendroglioma-Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Oligodendroglioma-Companies Involved in Therapeutics Development 21

AngioChem Inc 21

Boehringer Ingelheim GmbH 21

Bristol-Myers Squibb Co 21

Cavion LLC 22

Celldex Therapeutics Inc 22

Eli Lilly and Co 23

F. Hoffmann-La Roche Ltd 23

Immatics Biotechnologies GmbH 24

Ipsen SA 24

Leadiant Biosciences Inc 24

Millennium Pharmaceuticals Inc 25

Northwest Biotherapeutics Inc 25

Novartis AG 26

Pfizer Inc 26

Tocagen Inc 27

Oligodendroglioma-Drug Profiles 28

abemaciclib-Drug Profile 28

afatinib dimaleate-Drug Profile 36

alisertib-Drug Profile 50

bevacizumab-Drug Profile 56

CDX-1401-Drug Profile 68

Cellular Immunotherapy for Gliomas-Drug Profile 71

Cellular Immunotherapy for Oncology-Drug Profile 72

dasatinib-Drug Profile 73

DCVax-L-Drug Profile 77

flucytosine + TBio-01-Drug Profile 85

flucytosine ER + vocimagene amiretrorepvec-Drug Profile 86

IMA-950-Drug Profile 96

irinotecan hydrochloride-Drug Profile 98

irinotecan hydrochloride + TBio-02-Drug Profile 110

mibefradil dihydrochloride-Drug Profile 112

nilotinib-Drug Profile 115

p28-Drug Profile 122

paclitaxel trevatide-Drug Profile 124

palbociclib-Drug Profile 129

procarbazine hydrochloride-Drug Profile 142

TBX.OncV NSC-Drug Profile 143

Oligodendroglioma-Dormant Projects 144

Oligodendroglioma-Discontinued Products 145

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net